A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would ...

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...

Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

Sarepta Therapeutics ( ($SRPT) ) has issued an announcement. On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to ...

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 8% on Thursday after the rare disease medicine specialist announced it would refinance approximately $291 million of its convertible ...

Sarepta Therapeutics (SRPT) has quietly staged a sharp rebound over the past month, even though the longer term chart still looks bruised. That mix of momentum and past damage naturally raises ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.